Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22:17:223-232.
doi: 10.2147/TCRM.S271445. eCollection 2021.

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Oriana Simonetti #  1 , Giulio Rizzetto #  1 , Elisa Molinelli  1 , Oscar Cirioni  2 , Annamaria Offidani  1
Affiliations
Review

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Oriana Simonetti et al. Ther Clin Risk Manag. .

Abstract

Introduction: Dalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Methods: We conducted a narrative review of the literature on the safety profile of dalbavancin. The bibliographic research was carried out on the PubMed database on 6 November 2020 by seeking combinations of the following keywords: dalbavancin, adverse effects, safety, drug interactions, and skin infections.

Results: Five double-blind Phase 3 randomized clinical trials, 2 open-label randomized trials, and 4 retrospective studies were identified. No statistically significant differences were found between dalbavancin and comparators in the incidence of adverse events. Retrospective studies confirm the low incidence of adverse events.

Conclusion: Dalbavancin is a therapeutic option that has demonstrated an excellent safety profile, also in relation to the other MRSA therapies available. Its use represents a cost-effective solution for the treatment of those patients with ABSSSI who would need hospitalization. One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events.

Keywords: ABSSSI; adverse events; dalbavancin; safety; skin infections.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Dalvance prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lblpdf. Accessed November10, 2020.
    1. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptides. Antimicrob Agents Chemother. 2005;49(2):770–772. doi:10.1128/AAC.49.2.770-772.2005 - DOI - PMC - PubMed
    1. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). Int J Antimicrob Agents. 2018;51:608–611. doi:10.1016/j.ijantimicag.2017.12.011 - DOI - PubMed
    1. Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther. 2015;4:245–258. doi:10.1007/s40121-015-0077-7 - DOI - PMC - PubMed
    1. Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020;56(4):106107. doi:10.1016/j.ijantimicag.2020.106107 - DOI - PubMed

LinkOut - more resources